|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guo H, Wu T, Lu Q, Li M, Guo JY, Shen Y,
Wu Z, Nan KJ, Lv Y and Zhang XF: Surgical resection improves
long-term survival of patients with hepatocellular carcinoma across
different Barcelona clinic liver cancer stages. Cancer Manag Res.
10:361–369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z,
Deng X, Chen H, Shen B, Peng C, et al: Upregulation of long
noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor
prognosis in hepatocellular carcinoma. Oncogene. 35:1575–1584.
2016. View Article : Google Scholar
|
|
4
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kudo M: Systemic therapy for
hepatocellular carcinoma: Latest advances. Cancers (Basel). 10:pii:
E412. 2018. View Article : Google Scholar :
|
|
6
|
Augello G, Emma MR, Cusimano A, Azzolina
A, Mongiovi S, Puleio R, Cassata G, Gulino A, Belmonte B,
Gramignoli R, et al: Targeting HSP90 with the small molecule
inhibitor AUY922 (luminespib) as a treatment strategy against
hepatocellular carcinoma. Int J Cancer. Nov 29–2018.Epub ahead of
print. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harris WP, Wong KM, Saha S, Dika IE and
Abou-Alfa GK: Biomarker-driven and molecular targeted therapies for
hepato-biliary cancers. Semin Oncol. 45:116–123. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Q, Wei L, Yang H, Yang W, Yang Q,
Zhang Z, Wu K and Wu J and Wu J: Bromodomain containing protein
represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma
cell proliferation during HCV infection. Cancer Lett. 371:107–116.
2016. View Article : Google Scholar
|
|
9
|
Chai S, Ng KY, Tong M, Lau EY, Lee TK,
Chan KW, Yuan YF, Cheung TT, Cheung ST, Wang XQ, et al: Octamer
4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in
liver cancer stem cells. Hepatology. 64:2062–2076. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ou DL, Lee BS, Lin LI, Liou JY, Liao SC,
Hsu C and Cheng AL: Vertical blockade of the IGFR- PI3K/Akt/mTOR
pathway for the treatment of hepatocellular carcinoma: The role of
survivin. Mol Cancer. 13:22014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vivanco I and CL S: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 7:489–501. 2002. View
Article : Google Scholar
|
|
12
|
Presnell JS, Schnitzler CE and Browne WE:
KLF/SP Transcription factor family evolution: Expansion,
diversification, and innovation in eukaryotes. Genome Biol Evol.
7:2289–2309. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu JH, Navas P, Cao H, Stamatoyannopoulos
G and Song CZ: Systematic RNAi studies on the role of Sp/KLF
factors in globin gene expression and erythroid differentiation. J
Mol Biol. 366:1064–1073. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carrano AC, Dillin A and Hunter T: A
Krüppel-like factor downstream of the E3 ligase WWP-1 mediates
dietary-restriction-induced longevity in Caenorhabditis elegans.
Nat Commun. 5:37722014. View Article : Google Scholar
|
|
15
|
Kim CK, He P, Bialkowska AB and Yang VW:
SP and KLF transcription factors in digestive physiology and
diseases. Gastroenterology. 152:1845–1875. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen HY, Lin YM, Chung HC, Lang YD, Lin
CJ, Huang J, Wang WC, Lin FM, Chen Z, Huang HD, et al: miR-103/107
promote metastasis of colorectal cancer by targeting the metastasis
suppressors DAPK and KLF4. Cancer Res. 72:3631–3641. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Malak PN, Dannenmann B, Hirth A, Rothfuss
OC and Schulze-Osthoff K: Novel AKT phosphorylation sites
identified in the pluripotency factors OCT4, SOX2 and KLF4. Cell
Cycle. 14:3748–3754. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hsu YY, Liu CM, Tsai HH, Jong YJ, Chen IJ
and Lo YC: KMUP-1 attenuates serum deprivation-induced
neurotoxicity in SH-SY5Y cells: Roles of PKG, PI3K/Akt and
Bcl-2/Bax pathways. Toxicology. 268:46–54. 2010. View Article : Google Scholar
|
|
19
|
Muir KR, Lima MJ, Docherty HM, McGowan NW,
Forbes S, Heremans Y, Forbes SJ, Heimberg H, Casey J and Docherty
K: Krüppel-Like factor 4 overexpression initiates a
mesenchymal-to-epithelial transition and redifferentiation of human
pancreatic cells following expansion in long term adherent culture.
PLoS One. 10:e01403522015. View Article : Google Scholar
|
|
20
|
Sun H, Peng Z, Tang H, Xie D, Jia Z, Zhong
L, Zhao S, Ma Z, Gao Y, Zeng L, et al: Loss of KLF4 and
consequential downregulation of Smad7 exacerbate oncogenic TGF-β
signaling in and promote progression of hepatocellular carcinoma.
Oncogene. 36:2957–2968. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang YL, Zhou PJ, Wei L, Li W, Ji Z, Fang
YX and Gao WQ: MicroRNA-7 inhibits the stemness of prostate cancer
stem-like cells and tumorigenesis by repressing KLF4/PI3K/Akt/p21
pathway. Oncotarget. 6:24017–24031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Z, Zhao J, Li Q, Yang W, Song Q, Li W
and Liu J: KLF4 promotes hydrogen-peroxide-induced apoptosis of
chronic myeloid leukemia cells involving the bcl-2/bax pathway.
Cell Stress Chaperones. 15:905–912. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Q, Gao Y, Jia Z, Mishra L, Guo K, Li Z,
Le X, Wei D, Huang S and Xie K: Dysregulated Krüppel-like factor 4
and vitamin D receptor signaling contribute to progression of
hepatocellular carcinoma. Gastroenterology. 143:799–810.e2. 2012.
View Article : Google Scholar
|
|
24
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang LQ, Zhang Y, Yan H, Liu KJ and Zhang
S: MicroRNA-373 functions as an oncogene and targets YOD1 gene in
cervical cancer. Biochem Biophys Res Commun. 459:515–520. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yuan J, Ji H, Xiao F, Lin Z, Zhao X, Wang
Z, Zhao J and Lu J: MicroRNA-340 inhibits the proliferation and
invasion of hepa-tocellular carcinoma cells by targeting JAK1.
Biochem Biophys Res Commun. 483:578–584. 2017. View Article : Google Scholar
|
|
27
|
Yao S, Tian C, Ding Y, Ye Q, Gao Y, Yang N
and Li Q: Down-regulation of Krüppel-like factor-4 by
microRNA-135a-5p promotes proliferation and metastasis in
hepatocellular carcinoma by transforming growth factor-β1.
Oncotarget. 7:42566–42578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mirihana Arachchilage G, Kharel P, Reid J
and Basu S: Targeting of G-quadruplex harboring Pre-miRNA 92b by
LNA rescues PTEN expression in NSCL cancer cells. ACS Chem Biol.
13:909–914. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Varnholt H, Drebber U, Schulze F,
Wedemeyer I, Schirmacher P, Dienes HP and Odenthal M: MicroRNA gene
expression profile of hepatitis C virus-associated hepatocellular
carcinoma. Hepatology. 47:1223–1232. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
'personalized' approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kamarajah SK, Frankel TL, Sonnenday C, Cho
CS and Nathan H: Critical evaluation of the American joint
commission on cancer (AJCC) 8th edition staging system for patients
with hepatocellular carcinoma (HCC): A surveillance, epidemiology,
end results (SEER) analysis. J Surg Oncol. 117:644–650. 2018.
View Article : Google Scholar
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
33
|
Zawada AM, Rogacev KS, Muller S, Rotter B,
Winter P, Fliser D and Heine GH: Massive analysis of cDNA Ends
(MACE) and miRNA expression profiling identifies proatherogenic
pathways in chronic kidney disease. Epigenetics. 9:161–172. 2014.
View Article : Google Scholar :
|
|
34
|
Wang GC, He QY, Tong DK, Wang CF, Liu K,
Ding C, Ji F and Zhang H: MiR-367 negatively regulates apoptosis
induced by adriamycin in osteosarcoma cells by targeting KLF4. J
Bone Oncol. 5:51–56. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guo Y, An R, Zhao R, Sun Y, Liu M and Tian
L: miR-375 exhibits a more effective tumor-suppressor function in
laryngeal squamous carcinoma cells by regulating KLF4 expression
compared with simple co-transfection of miR-375 and miR-206. Oncol
Rep. 36:952–960. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Braconi C and Patel T: Non-coding RNAs as
therapeutic targets in hepatocellular cancer. Curr Cancer Drug
Targets. 12:1073–1080. 2012.PubMed/NCBI
|
|
37
|
Zimmermann TS, Lee AC, Akinc A, Bramlage
B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M,
et al: RNAi-mediated gene silencing in non-human primates. Nature.
441:111–114. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Klingenberg M, Matsuda A, Diederichs S and
Patel T: Non-coding RNA in hepatocellular carcinoma: Mechanisms,
biomarkers and therapeutic targets. J Hepatol. 67:603–618. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hayes CN and Chayama K: MicroRNAs as
biomarkers for liver disease and hepatocellular carcinoma. Int J
Mol Sci. 17:2802016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
He S, Zhang DC and Wei C: MicroRNAs as
biomarkers for hepa-tocellular carcinoma diagnosis and prognosis.
Clin Res Hepatol Gastroenterol. 39:426–434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang N, Ekanem NR, Sakyi CA and Ray SD:
Hepatocellular carcinoma and microRNA: New perspectives on
therapeutics and diagnostics. Adv Drug Deliv Rev. 81:62–74. 2015.
View Article : Google Scholar
|
|
42
|
Fang F, Chang RM, Yu L, Lei X, Xiao S,
Yang H and Yang LY: MicroRNA-188-5p suppresses tumor cell
proliferation and metastasis by directly targeting FGF5 in
hepatocellular carcinoma. J Hepatol. 63:874–885. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ma S, Tang KH, Chan YP, Lee TK, Kwan PS,
Castilho A, Ng I, Man K, Wong N, To KF, et al: miR-130b promotes
CD133(+) liver tumor-initiating cell growth and self-renewal via
tumor protein 53-induced nuclear protein 1. Cell Stem Cell.
7:694–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Missiaglia E, Shepherd CJ, Aladowicz E,
Olmos D, Selfe J, Pierron G, Delattre O, Walters Z and Shipley J:
MicroRNA and gene co-expression networks characterize biological
and clinical behavior of rhabdomyosarcomas. Cancer Lett.
385:251–260. 2017. View Article : Google Scholar :
|
|
45
|
Guo LM, Pu Y, Han Z, Liu T, Li TX, Liu M,
Li X and Tang H: MicroRNA-9 inhibits ovarian cancer cell growth
through regulation of NF-kappaB1. FEBS J. 276:5537–5546. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Han D, Li J, Wang H, Su X, Hou J, Gu Y,
Qian C, Lin Y, Liu X, Huang M, et al: Circular RNA circMTO1 acts as
the sponge of microRNA-9 to suppress hepatocellular carcinoma
progression. Hepatology. 66:1151–1164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tang W, Zhu Y, Gao J, Fu J, Liu C, Liu Y,
Song C, Zhu S, Leng Y, Wang G, et al: MicroRNA-29a promotes
colorectal cancer metastasis by regulating matrix metalloproteinase
2 and E-cadherin via KLF4. Br J Cancer. 110:450–458. 2014.
View Article : Google Scholar :
|
|
48
|
Calvisi DF, Wang C, Ho C, Ladu S, Lee SA,
Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, et al:
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling,
promotes development of human hepatocellular carcinoma.
Gastroenterology. 140:1071–1083. 2011. View Article : Google Scholar :
|
|
49
|
Fang Y, Xue JL, Shen Q, Chen J and Tian L:
MicroRNA-7 inhibits tumor growth and metastasis by targeting the
phos-phoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.
Hepatology. 55:1852–1862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hata AN, Engelman JA and Faber AC: The
BCL2 family: Key mediators of the apoptotic response to targeted
anticancer therapeutics. Cancer Discov. 5:475–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
